S. Bujassoum

发表

Isolated Central Nervous System Relapse in Lymphoid Blast Crisis Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Patients on Imatinib Therapy

J. Lipton, S. Bujassoum, J. Rifkind, 2004, Leukemia & lymphoma.

QATAR’S EXPERIENCE WITH HEREDITARY BREAST AND OVARIAN CANCER AND HIGH RISK CLINIC: A RETROSPECTIVE STUDY 2013- 2016

H. Bugrein, H. Ghazouani, S. Bujassoum, 2017 .

Genotype and Phenotype Correlation of Breast Cancer in BRCA MutationCarriers and Non-Carriers

H. Bugrein, R. Alsulaiman, S. Bujassoum, 2015 .

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

M. Burotto, L. Fallowfield, S. Margolin, 2021, European journal of cancer.

Immunocompromised Patient with Bilateral Pulmonary Infiltrates (Docetaxel Induced Hypersensitivity Interstitial Pneumonitis)

S. Bujassoum, N. Najjar, S. A. Azawi, 2010 .

A Grave Outcome of Posterior Reversible Encephalopathy Syndrome in a Patient Receiving Avastin (Bevacizumab) for Metastatic High-Grade Serous Ovarian Cancer

S Elazzazy, Khaled S. Salem, S. Bujassoum, 2015, Case Reports in Oncology.

Identifying Lynch Syndrome in Two Families with Classical Hereditary Breast and Ovarian Cancer Syndrome Phenotype: A Case Report

A. Mahfouz, H. Farghaly, R. Alsulaiman, 2018 .

Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy. Retrospective study in early stage ER positive breast cancer

F. Salih, K. Rasul, M. Elmistiri, 2018, Annals of Breast Cancer.

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

S Elazzazy, S. Bujassoum, M. I. Mohamed Ibrahim, 2024, Frontiers in oncology.